Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-17-002649
Filing Date
2017-03-16
Accepted
2017-03-16 17:07:00
Documents
6
Period of Report
2017-04-25
Effectiveness Date
2017-03-16

Document Format Files

Seq Description Document Type Size
1 DEF 14A 2017 PROXY STATEMENT a2017proxystatement.htm DEF 14A 682868
2 ajbackgroundpicture.jpg GRAPHIC 10605
3 cumberlandlogoa02a01.jpg GRAPHIC 12534
4 cumberlandpharmalogoa01.jpg GRAPHIC 37721
5 untitleda01a01.jpg GRAPHIC 9167
6 xa01.jpg GRAPHIC 2405
  Complete submission text file 0001628280-17-002649.txt   784270
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: DEF 14A | Act: 34 | File No.: 001-33637 | Film No.: 17695377
SIC: 2834 Pharmaceutical Preparations